JAK/TYK2
REstream Block (Upcoming)
Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…
1 year 3 months ago
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
1 year 3 months ago
JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
1 year 3 months ago
Abstracts talking about #RA and JAKs and Biologic comparisons
Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below
@RheumNow https://t.co/jl5S4fLq19
Podcasts
Systemic Sclerosis Insights (9.13.2024)-
Linger On The Fingers (9.6.2024)
Earlier treatment with biologics to reduce the risk of organ damage
Poster Hall